期刊
THERANOSTICS
卷 12, 期 5, 页码 2115-2132出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.69424
关键词
Platinum-based drugs; Cancer therapy; Anti-cancer mechanism; Systemic toxicity; Platinum nanoclusters
资金
- National Natural Science Foundation of China [21727817, U2067214, 11621505]
- Academic Promotion Program of Shandong First Medical University [2019LJ003]
This article discusses the application and development of platinum-based drugs in cancer treatment, particularly the targeted modification of platinum nanoclusters. The new platinum drugs provide a promising prospect for improving anti-cancer treatments.
Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer. However, the side effects of platinum drugs, such as lack of selectivity, high systemic toxicity, and drug resistance, seriously limit their clinical application. With advancements in nanotechnology and chemical synthesis, Pt-based anti-cancer drugs have made great progress in cancer therapy in recent years. Many strategies relied on the anti-cancer mechanism similar to cisplatin and achieved some success by modifying existing platinum drugs. Pt-based nanodrugs, such as platinum nanoclusters, have novel anti-cancer mechanisms and great potential in tumor-targeted therapy and have shown promising results in clinical application. In this review, we systematically explored the development of first-line platinum chemotherapy drugs in the clinic and their anti-cancer mechanisms. We also summarize the progress of Pt-based anti-cancer drug application in cancer therapy, emphasizing their modification to enhance the anti-tumor effect. Finally, we address challenges faced by platinum chemotherapy drugs, especially Pt nanocluster-based nanodrugs, in cancer treatment. The new platinum drugs and their targeted modifications undoubtedly provide a promising prospect for improving the current anti-cancer treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据